Wendy Su

773 total citations
49 papers, 412 citations indexed

About

Wendy Su is a scholar working on Pathology and Forensic Medicine, Urban Studies and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Wendy Su has authored 49 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pathology and Forensic Medicine, 7 papers in Urban Studies and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Wendy Su's work include Multiple Sclerosis Research Studies (18 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Cultural Industries and Urban Development (7 papers). Wendy Su is often cited by papers focused on Multiple Sclerosis Research Studies (18 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Cultural Industries and Urban Development (7 papers). Wendy Su collaborates with scholars based in United States, Switzerland and Germany. Wendy Su's co-authors include Sungchil Yang, Shaowen Bao, Anne H. Cross, Bernd C. Kieseier, Ratnakar Pingili, Dieter A. Häring, Stephen L. Hauser, Roman Willi, Ludwig Kappos and Prakash Krishnan and has published in prestigious journals such as Neurology, Journal of Neurophysiology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Wendy Su

41 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wendy Su United States	13	192	82	68	58	49	49	412
Thomas Le Roux France	10	100 0.5×	56 0.7×	69 1.0×	52 0.9×	2 0.0×	56	417
Josephine M. Guy United States	13	78 0.4×	123 1.5×	28 0.4×	18 0.3×	8 0.2×	50	813
Andrew J. Wilson United Kingdom	11	29 0.2×	25 0.3×	74 1.1×	20 0.3×	14 0.3×	30	455
Eleonora Rosati United Kingdom	15	14 0.1×	101 1.2×	19 0.3×	42 0.7×	4 0.1×	98	641
Jacob M. Landau Israel	18	110 0.6×	25 0.3×	416 6.1×	14 0.2×	33 0.7×	144	1.1k
Ekkehard Kasper United States	14	102 0.5×	201 2.5×	20 0.3×	4 0.1×	2 0.0×	33	654
Eva Kučerová Czechia	6	10 0.1×	23 0.3×	38 0.6×	11 0.2×	5 0.1×	16	332
Rebecca O’Rourke United States	13	22 0.1×	24 0.3×	32 0.5×	37 0.6×	7 0.1×	45	685
Ryan J. Gallagher United States	11	43 0.2×	97 1.2×	125 1.8×	20 0.3×	6 0.1×	15	591
J.J.A. Mooij Netherlands	10	20 0.1×	175 2.1×	70 1.0×	24 0.4×	4 0.1×	32	663

Countries citing papers authored by Wendy Su

Since Specialization

Citations

This map shows the geographic impact of Wendy Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Su more than expected).

Fields of papers citing papers by Wendy Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Su. The network helps show where Wendy Su may publish in the future.

Co-authorship network of co-authors of Wendy Su

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Su. A scholar is included among the top collaborators of Wendy Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Su. Wendy Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chong, Yap Seng, Wendy Su, William G. Wilson, et al.. (2025). P1225 A cross-sectional study of Inflammatory Bowel Disease in older people across Australasia, a Crohn’s Colitis Cure data insights program. Journal of Crohn s and Colitis. 19(Supplement_1). i2216–i2217.

Su, Wendy, William R. Wilson, Kate D. Lynch, et al.. (2025). P1281 Active perianal fistulising Crohn’s Disease is associated with a higher burden of psychological distress, depression, anxiety, stress and opioid use. Journal of Crohn s and Colitis. 19(Supplement_1). i2311–i2312. 1 indexed citations

Ocampo, Alex, Jelena Čuklina, Gordon Graham, et al.. (2024). Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model. Multiple Sclerosis Journal. 30(11-12). 1455–1467.

Hutchinson, Brian, et al.. (2023). Orchestrating a New Path for Multiple Sclerosis: Achieving Physical, Cognitive, and Emotional Rehabilitation Goals Through Physical and Music Therapy. International Journal of MS Care. 25(4). 168–175. 1 indexed citations

Diyaolu, Modupeola, et al.. (2023). Outcome assessment of office Plastibell circumcision in infants utilizing interactive electronic health record. Journal of Pediatric Surgery. 58(5). 1008–1013. 1 indexed citations

Overeem, Lucas Hendrik, Bianca Raffaelli, Robert Fleischmann, et al.. (2023). Serum tau protein elevation in migraine: a cross-sectional case–control study. The Journal of Headache and Pain. 24(1). 130–130. 8 indexed citations

Hua, Le H., Amit Bar‐Or, Stanley Cohan, et al.. (2023). Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study. Multiple Sclerosis and Related Disorders. 75. 104766–104766. 5 indexed citations

Hodgkinson, Suzanne, Stephen L. Hauser, Edward Edward, et al.. (2022). 2265 Long-term efficacy of ofatumumab in patients with relapsing multiple sclerosis. Abstracts. A26.2–A26.

Yu, Shengyuan, Byung‐Kun Kim, Hebo Wang, et al.. (2022). A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. The Journal of Headache and Pain. 23(1). 146–146. 12 indexed citations

10.

Hauser, Stephen L., Edward Fox, Wendy Su, et al.. (2022). Long-term Efficacy of Ofatumumab in Patients With Relapsing Multiple Sclerosis (P5-4.004). Neurology. 98(18_supplement). 3 indexed citations

11.

Cross, Anne H., Silvia Delgado, Mario Habek, et al.. (2022). COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. Neurology and Therapy. 11(2). 741–758. 20 indexed citations

12.

John, Nevin, John F. Kramer, Ratnakar Pingili, et al.. (2022). 2323 Injection-related reactions with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: data from clinical studies and post marketing experience. Abstracts. A38.2–A38.

13.

Ziemssen, Tjalf, Douglas L. Arnold, Enrique Álvarez, et al.. (2022). Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology. 13. 852563–852563. 28 indexed citations

14.

Hauser, Stephen L., Anne H. Cross, Kevin Winthrop, et al.. (2022). Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple Sclerosis Journal. 28(10). 1576–1590. 45 indexed citations

15.

Gärtner, Jutta, Stephen L. Hauser, Amit Bar‐Or, et al.. (2022). Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Multiple Sclerosis Journal. 28(10). 1562–1575. 55 indexed citations

16.

Delgado, Silvia, Mitzi Williams, Morten Bagger, et al.. (2021). Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the ASCLEPIOS I/II and APOLITOS studies (4139). Neurology. 96(15_supplement). 2 indexed citations

17.

Lewis, Sandy, Sibyl Wray, Emily Evans, et al.. (2021). Patients’ Experiences in Transitioning to Secondary Progressive Multiple Sclerosis: Qualitative Interviews. Neurology and Therapy. 10(2). 887–904.

18.

Álvarez, Enrique, Kavita Nair, Yao Ding, et al.. (2021). Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey. Multiple Sclerosis and Related Disorders. 50. 102858–102858. 1 indexed citations

19.

Cutter, Gary, Xiangyi Meng, Amit Bar‐Or, et al.. (2020). Effect of Siponimod on Disability in EXPAND Re-examined with Two New Subscales of the Expanded Disability Status Scale in Patients with SPMS (4051). Neurology. 94(15_supplement). 1 indexed citations

20.

Inglese, Matilde, Maria Petracca, Sirio Cocozza, et al.. (2018). Final MRI Results At 6 Months From A Phase 2 Multicenter Study Of Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), In Patients With Relapsing Forms Of Multiple Sclerosis (RMS), Demonstrates Complete Elimination Of Gd-Enhancing Lesions (P3.409). Neurology. 90(15_supplement). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact